A 70-year-old man with Parkinson disease controlled on levodopa/carbidopa for 5 years develops psychotic symptoms. His neurologist considers adding an antipsychotic but is concerned about worsening parkinsonism. His family reports he has good motor control currently but the hallucinations are distressing. Evaluate the most appropriate antipsychotic choice considering the drug interaction profile.
Q2
A 35-year-old woman taking combined oral contraceptives for 2 years develops a breakthrough seizure. She is started on carbamazepine for newly diagnosed epilepsy. Four weeks later, she presents with irregular vaginal bleeding and is concerned about contraceptive failure. Apply pharmacological principles to explain the most appropriate management.
Q3
A 58-year-old man with type 2 diabetes on metformin and a recent kidney transplant on tacrolimus presents with persistent hyperglycemia. His nephrologist wants to optimize diabetic control while maintaining stable immunosuppression. His tacrolimus trough level has been stable at 8 ng/mL. Evaluate the safest approach to intensify diabetes management.
Q4
A 42-year-old woman with major depression has failed multiple SSRI trials. Her psychiatrist initiates phenelzine (MAOI). Two weeks later, she develops severe headache, diaphoresis, and hypertension (BP 210/120 mmHg) after eating at a restaurant. Which food item most likely precipitated this hypertensive crisis?
Q5
A 62-year-old man with heart failure is on digoxin, furosemide, and spironolactone. He develops acute gout and his primary care physician prescribes indomethacin. One week later, he presents with nausea, visual disturbances (yellow halos), and cardiac arrhythmias. His digoxin level is elevated at 3.2 ng/mL (therapeutic: 0.5-2.0). Analyze the most likely mechanism contributing to digoxin toxicity in this patient.
Q6
A 38-year-old woman with epilepsy well-controlled on phenytoin for 5 years presents requesting oral contraceptives. Her seizures have been absent for 3 years. She is concerned about pregnancy. What is the most appropriate counseling regarding this drug combination?
Q7
A 72-year-old woman with chronic pain on long-term oxycodone therapy develops a urinary tract infection. She is prescribed clarithromycin. Three days later, she presents to the emergency department with severe sedation, respiratory depression (respiratory rate 8/min), and pinpoint pupils. Evaluate the most appropriate immediate management considering the underlying drug interaction.
Q8
A 55-year-old man with HIV on a stable antiretroviral regimen including ritonavir presents with new-onset chest pain. Cardiac catheterization reveals significant coronary artery disease requiring stent placement. The cardiologist wants to start clopidogrel for dual antiplatelet therapy. What is the most important consideration regarding this drug combination?
Q9
A 45-year-old woman with bipolar disorder controlled on lithium presents with confusion, tremor, and ataxia. Her lithium level is 2.8 mEq/L (therapeutic: 0.6-1.2). She recently started a new medication prescribed by her primary care physician for hypertension. Which antihypertensive medication most likely caused this interaction?
Q10
A 68-year-old man with atrial fibrillation on warfarin (INR 2.5) presents to the emergency department with severe back pain. He was started on ciprofloxacin 3 days ago for a urinary tract infection. Today his INR is 6.2 and he has no signs of bleeding. Which mechanism best explains this drug interaction?
Drug interactions and adverse effects US Medical PG Practice Questions and MCQs
Question 1: A 70-year-old man with Parkinson disease controlled on levodopa/carbidopa for 5 years develops psychotic symptoms. His neurologist considers adding an antipsychotic but is concerned about worsening parkinsonism. His family reports he has good motor control currently but the hallucinations are distressing. Evaluate the most appropriate antipsychotic choice considering the drug interaction profile.
A. Haloperidol, as first-generation antipsychotics are most effective for psychosis
B. Risperidone, using the lowest effective dose to minimize motor effects
C. Quetiapine or clozapine, as they have minimal dopamine D2 receptor blockade in the nigrostriatal pathway (Correct Answer)
D. Olanzapine, which has moderate D2 blockade balancing efficacy and side effects
E. Aripiprazole, as a partial dopamine agonist will not worsen parkinsonism
Explanation: ***Quetiapine or clozapine, as they have minimal dopamine D2 receptor blockade in the nigrostriatal pathway***
- These specific **atypical antipsychotics** have very low affinity for **D2 receptors** and rapid dissociation rates, which preserves motor function in the **nigrostriatal pathway**.
- **Quetiapine** is generally the first-line choice for **Parkinson disease psychosis** due to its safety profile, while **clozapine** is highly effective but requires monitoring for **agranulocytosis**.
*Haloperidol, as first-generation antipsychotics are most effective for psychosis*
- **Haloperidol** is a potent **D2 receptor antagonist** that significantly worsens motor symptoms in Parkinson disease by blocking remaining dopamine activity.
- It carries a high risk of inducing **extrapyramidal symptoms (EPS)** and should be strictly avoided in patients with movement disorders.
*Risperidone, using the lowest effective dose to minimize motor effects*
- Even at low doses, **risperidone** often exhibits enough **D2 blockade** to exacerbate tremor and bradykinesia in Parkinson patients.
- It has a higher propensity for causing **dose-dependent parkinsonism** compared to quetiapine or clozapine.
*Olanzapine, which has moderate D2 blockade balancing efficacy and side effects*
- **Olanzapine** has been shown in clinical trials to worsen Parkinson motor symptoms without providing superior efficacy for **hallucinations**.
- Its **moderate D2 occupancy** is still high enough to interfere with the therapeutic goals of **Levodopa** therapy.
*Aripiprazole, as a partial dopamine agonist will not worsen parkinsonism*
- Although it is a **partial agonist**, its high binding affinity allows it to act as a functional antagonist in the presence of existing **dopaminergic therapy**.
- Clinical evidence suggests **aripiprazole** can paradoxically worsen parkinsonian features and is not recommended for this patient population.
Question 2: A 35-year-old woman taking combined oral contraceptives for 2 years develops a breakthrough seizure. She is started on carbamazepine for newly diagnosed epilepsy. Four weeks later, she presents with irregular vaginal bleeding and is concerned about contraceptive failure. Apply pharmacological principles to explain the most appropriate management.
A. Reassure that breakthrough bleeding is normal with carbamazepine and continue current contraception
B. Switch to higher-dose oral contraceptives or alternative contraception due to enzyme induction (Correct Answer)
C. Discontinue carbamazepine and choose a non-enzyme-inducing antiepileptic
D. Add supplemental estrogen to the current contraceptive regimen
E. Perform pregnancy test and continue current medications if negative
Explanation: ***Switch to higher-dose oral contraceptives or alternative contraception due to enzyme induction***
- **Carbamazepine** is a potent **inducer of cytochrome P450 enzymes (CYP3A4)**, which significantly accelerates the metabolism of estrogen and progestogen components in oral contraceptives.
- The resulting **reduced serum levels** of hormones lead to breakthrough bleeding and a high risk of **unintended pregnancy**, necessitating a more robust contraceptive strategy.
*Reassure that breakthrough bleeding is normal with carbamazepine and continue current contraception*
- Breakthrough bleeding in this context is a clinical sign of **sub-therapeutic hormone levels**, not a benign side effect of carbamazepine itself.
- Failing to adjust the regimen leaves the patient at significant **risk of contraceptive failure** due to the drug interaction.
*Discontinue carbamazepine and choose a non-enzyme-inducing antiepileptic*
- While switching to agents like **levetiracetam** is possible, carbamazepine might already be effective for her **seizure control**, and pharmacological management can often be handled by adjusting the contraceptive method instead.
- Abruptly discontinuing an effective **antiepileptic drug (AED)** can provoke withdrawal seizures or **status epilepticus**.
*Add supplemental estrogen to the current contraceptive regimen*
- Simply adding supplemental doses of estrogen is not standardized and does not address the **accelerated metabolism** of the progestogen component, which is vital for contraception.
- Standard guidelines recommend using a higher-dose **combined pill (at least 50mcg ethinylestradiol)** or switching to a method unaffected by induction, such as a **copper IUD**.
*Perform pregnancy test and continue current medications if negative*
- Testing for pregnancy is appropriate for evaluation, but continuing the current medications without changes fails to address the ongoing **pharmacokinetic interaction**.
- Continuing the same regimen ensures that the **efficacy of the oral contraceptive** remains compromised, leading to a high probability of future failure.
Question 3: A 58-year-old man with type 2 diabetes on metformin and a recent kidney transplant on tacrolimus presents with persistent hyperglycemia. His nephrologist wants to optimize diabetic control while maintaining stable immunosuppression. His tacrolimus trough level has been stable at 8 ng/mL. Evaluate the safest approach to intensify diabetes management.
A. Add glipizide as it has no interaction with tacrolimus
B. Switch to insulin therapy while monitoring tacrolimus levels closely (Correct Answer)
C. Add pioglitazone which improves insulin sensitivity
D. Increase metformin dose and add sitagliptin
E. Add glyburide for better glycemic control
Explanation: ***Switch to insulin therapy while monitoring tacrolimus levels closely***
- **Insulin** is the gold standard for managing **post-transplantation diabetes mellitus (PTDM)** because it lacks metabolic interactions with **calcineurin inhibitors** like tacrolimus.
- It provides precise glycemic control and avoids the potential nephrotoxicity or **CYP3A4** metabolic interference associated with various oral hypoglycemic agents.
*Add glipizide as it has no interaction with tacrolimus*
- While **glipizide** is primarily metabolized by CYP2C9, most **sulfonylureas** are less preferred in transplant patients due to the risk of **hypoglycemia** and variable pharmacokinetics.
- Sulfonylureas do not address the **insulin resistance** or beta-cell dysfunction often exacerbated by tacrolimus therapy as effectively as insulin.
*Add pioglitazone which improves insulin sensitivity*
- **Pioglitazone** can cause **fluid retention** and weight gain, which complicates the management of patients with a **kidney transplant** and potential cardiovascular risk.
- It is metabolized by **CYP3A4** and **CYP2C8**, which can lead to unpredictable drug-drug interactions with the tacrolimus metabolic pathway.
*Increase metformin dose and add sitagliptin*
- Increasing **metformin** in a recent transplant recipient is risky due to potential fluctuations in **Glomerular Filtration Rate (GFR)**, increasing the risk of **lactic acidosis**.
- While **DPP-4 inhibitors** like sitagliptin are generally safe, they are often insufficient for significant hyperglycemia and require renal dose adjustments.
*Add glyburide for better glycemic control*
- **Glyburide** is contraindicated if there is any degree of **renal impairment** (common post-transplant) due to the risk of prolonged, severe **hypoglycemia**.
- It has active metabolites that are **renally excreted**, making it a dangerous choice compared to alternative agents or insulin.
Question 4: A 42-year-old woman with major depression has failed multiple SSRI trials. Her psychiatrist initiates phenelzine (MAOI). Two weeks later, she develops severe headache, diaphoresis, and hypertension (BP 210/120 mmHg) after eating at a restaurant. Which food item most likely precipitated this hypertensive crisis?
A. Fresh mozzarella cheese
B. Grilled chicken breast
C. Aged cheddar cheese (Correct Answer)
D. Steamed vegetables
E. White rice
Explanation: ***Aged cheddar cheese***
- **Phenelzine** is a **Monoamine Oxidase Inhibitor (MAOI)** that blocks the breakdown of **tyramine**, an indirect sympathomimetic found in aged foods.
- Ingestion of tyramine-rich foods like **aged cheddar** leads to massive **norepinephrine** release, resulting in a **hypertensive crisis**, headache, and diaphoresis.
*Fresh mozzarella cheese*
- Unlike aged varieties, **fresh cheeses** (e.g., mozzarella, ricotta, cottage cheese) contain negligible amounts of **tyramine**.
- These are generally considered safe for patients on MAOIs and would not typically trigger a severe **sympathetic surge**.
*Grilled chicken breast*
- **Freshly prepared meats** are safe to consume; high tyramine levels only develop in meats that are **aged**, **fermented**, or **cured**.
- There is no clinical association between fresh poultry and the precipitation of **adrenergic crisis** in the context of MAOI therapy.
*Steamed vegetables*
- Most vegetables are safe; only specific items like **fava beans** or **overripe/fermented** plant products contain significant tyramine.
- **Steamed vegetables** lack the fermentation or aging process required to produce the toxic levels of amines that interact with **MAOIs**.
*White rice*
- **Grains** such as white rice are consistently low in tyramine and are not associated with **dietary drug interactions**.
- This side dish would not cause the **severe hypertension (210/120 mmHg)** observed in this clinical scenario.
Question 5: A 62-year-old man with heart failure is on digoxin, furosemide, and spironolactone. He develops acute gout and his primary care physician prescribes indomethacin. One week later, he presents with nausea, visual disturbances (yellow halos), and cardiac arrhythmias. His digoxin level is elevated at 3.2 ng/mL (therapeutic: 0.5-2.0). Analyze the most likely mechanism contributing to digoxin toxicity in this patient.
A. Indomethacin directly inhibits renal tubular secretion of digoxin
B. Indomethacin reduces renal perfusion, decreasing digoxin clearance, compounded by furosemide-induced hypokalemia (Correct Answer)
C. Spironolactone-induced hyperkalemia enhances digoxin binding to Na-K-ATPase
D. Indomethacin displaces digoxin from tissue binding sites
E. Furosemide-induced hypomagnesemia is the sole cause of digoxin toxicity
Explanation: ***Indomethacin reduces renal perfusion, decreasing digoxin clearance, compounded by furosemide-induced hypokalemia***
- **Indomethacin** (an NSAID) inhibits prostaglandins that maintain **renal blood flow**, leading to decreased **glomerular filtration** and clearance of digoxin.
- Concurrent use of **furosemide** can cause **hypokalemia**, which sensitizes the myocardium by enhancing **digoxin binding** to the Na+/K+-ATPase pump, exacerbating toxicity symptoms like **yellow halos** and arrhythmias.
*Indomethacin directly inhibits renal tubular secretion of digoxin*
- While some drugs like **verapamil** or **quinidine** inhibit P-glycoprotein-mediated secretion of digoxin, NSAIDs primarily affect **renal hemodynamics**.
- The rise in digoxin levels from NSAIDs is more closely linked to a reduction in the **Glomerular Filtration Rate (GFR)** rather than a specific secretory pump blockade.
*Spironolactone-induced hyperkalemia enhances digoxin binding to Na-K-ATPase*
- **Hyperkalemia** actually reduces the binding of digoxin to the Na+/K+-ATPase pump because potassium and digoxin **compete** for the same binding site.
- **Spironolactone** is a potassium-sparing diuretic that would typically counteract the hypokalemic effects of **furosemide**, rather than increasing digoxin toxicity through binding enhancement.
*Indomethacin displaces digoxin from tissue binding sites*
- Displacement from **tissue binding sites** (like skeletal muscle) is a classic mechanism for drugs like **quinidine**, not NSAIDs.
- **Indomethacin** toxicity is driven by its effects on **renal excretion** and physiology rather than changing the volume of distribution through protein or tissue displacement.
*Furosemide-induced hypomagnesemia is the sole cause of digoxin toxicity*
- While **hypomagnesemia** is a known risk factor that predisposes the heart to digoxin-induced **arrhythmias**, it is rarely the "sole" cause when blood levels are objectively elevated.
- The patient's **elevated digoxin level (3.2 ng/mL)** indicates a pharmacokinetic failure in **clearance**, which points toward renal impairment from indomethacin rather than just an electrolyte imbalance.
Question 6: A 38-year-old woman with epilepsy well-controlled on phenytoin for 5 years presents requesting oral contraceptives. Her seizures have been absent for 3 years. She is concerned about pregnancy. What is the most appropriate counseling regarding this drug combination?
A. Start standard oral contraceptives as phenytoin does not affect contraceptive efficacy
B. Phenytoin induces CYP3A4, reducing contraceptive efficacy; recommend barrier methods or higher-dose formulations (Correct Answer)
C. Oral contraceptives inhibit phenytoin metabolism, requiring phenytoin dose reduction
D. Use progesterone-only pills as they are not affected by phenytoin
E. Discontinue phenytoin since she has been seizure-free for 3 years
Explanation: ***Phenytoin induces CYP3A4, reducing contraceptive efficacy; recommend barrier methods or higher-dose formulations***
- **Phenytoin** is a potent inducer of the **cytochrome P450 system (CYP3A4)**, which significantly accelerates the metabolism of both estrogen and progestin.
- This interaction leads to **reduced serum levels** of contraceptives, increasing the failure rate and the risk of **unintended pregnancy**.
*Start standard oral contraceptives as phenytoin does not affect contraceptive efficacy*
- This statement is incorrect because **enzyme-inducing** anti-epileptic drugs (AEDs) like phenytoin have a well-documented **major drug interaction** with hormonal birth control.
- Standard low-dose pills are likely to fail due to **enhanced clearance** of the hormones required to suppress ovulation.
*Oral contraceptives inhibit phenytoin metabolism, requiring phenytoin dose reduction*
- While some drugs affect **phenytoin metabolism**, oral contraceptives do not significantly inhibit the **CYP2C9/2C19** pathways responsible for phenytoin clearance.
- The primary concern in this interaction is the **loss of contraceptive efficacy**, not **phenytoin toxicity**.
*Use progesterone-only pills as they are not affected by phenytoin*
- **Progesterone-only pills (POPs)** are also metabolized by the liver and are highly susceptible to **enzyme induction**, making them even less reliable than combined pills.
- Most guidelines suggest that **standard POPs** should be avoided in patients taking phenytoin due to the high risk of **ovulatory escape**.
*Discontinue phenytoin since she has been seizure-free for 3 years*
- Although she has been seizure-free, any decision to taper or **discontinue AED therapy** must be gradual and supervised by a **neurologist** after weighing the risk of relapse.
- Discontinuing therapy solely to facilitate standard oral contraceptive use is inappropriate clinical management when **alternative contraception** methods are available.
Question 7: A 72-year-old woman with chronic pain on long-term oxycodone therapy develops a urinary tract infection. She is prescribed clarithromycin. Three days later, she presents to the emergency department with severe sedation, respiratory depression (respiratory rate 8/min), and pinpoint pupils. Evaluate the most appropriate immediate management considering the underlying drug interaction.
A. Discontinue clarithromycin and observe for 24 hours
B. Administer naloxone and discontinue both medications (Correct Answer)
C. Switch clarithromycin to azithromycin and continue oxycodone
D. Reduce oxycodone dose by 50% and continue clarithromycin
E. Administer flumazenil for reversal of sedation
Explanation: ***Administer naloxone and discontinue both medications***
- The patient is experiencing life-threatening **opioid toxicity** (miosis, respiratory depression) caused by **clarithromycin**, a potent **CYP3A4 inhibitor** that decreased the metabolism of **oxycodone**.
- **Naloxone** is the immediate life-saving treatment to reverse respiratory depression, and both offending drugs must be stopped to prevent further accumulation.
*Discontinue clarithromycin and observe for 24 hours*
- This approach is dangerously slow because the patient's **respiratory rate** of 8/min indicates an acute medical emergency.
- Waiting for the drug levels to drop naturally without **naloxone** intervention risks **respiratory arrest** and death.
*Switch clarithromycin to azithromycin and continue oxycodone*
- While **azithromycin** does not inhibit CYP3A4, simply switching the antibiotic does not treat the current acute **opioid overdose**.
- Continuing **oxycodone** in a patient already suffering from severe toxic effects would exacerbate the sedation and **hypoventilation**.
*Reduce oxycodone dose by 50% and continue clarithromycin*
- Dose reduction is a preventative strategy, but it is insufficient for a patient already presenting with **toxic clinical signs**.
- **Clarithromycin** will continue to inhibit the metabolism of the remaining dose, maintaining dangerously high **plasma concentrations** of the opioid.
*Administer flumazenil for reversal of sedation*
- **Flumazenil** is a competitive antagonist for **benzodiazepines**, not opioids, and would be ineffective in this scenario.
- Administering flumazenil for an opioid overdose is inappropriate and can trigger **seizures** in patients with a co-ingestion or chronic use.
Question 8: A 55-year-old man with HIV on a stable antiretroviral regimen including ritonavir presents with new-onset chest pain. Cardiac catheterization reveals significant coronary artery disease requiring stent placement. The cardiologist wants to start clopidogrel for dual antiplatelet therapy. What is the most important consideration regarding this drug combination?
A. Ritonavir inhibits CYP3A4, but clopidogrel activation is primarily via CYP2C19
B. Ritonavir induces CYP2C19, leading to excessive clopidogrel activation and bleeding risk
C. Ritonavir inhibits CYP2C19, preventing clopidogrel conversion to its active metabolite (Correct Answer)
D. Clopidogrel induces ritonavir metabolism, decreasing antiretroviral efficacy
E. No significant interaction exists between these medications
Explanation: ***Ritonavir inhibits CYP2C19, preventing clopidogrel conversion to its active metabolite***
- **Clopidogrel** is a **prodrug** that requires a two-step oxidative process, primarily mediated by the **CYP2C19** enzyme, to become active.
- **Ritonavir** acts as a potent **inhibitor** of multiple cytochrome P450 enzymes, including CYP2C19, which reduces the plasma concentration of the active metabolite and increases the risk of **stent thrombosis**.
*Ritonavir inhibits CYP3A4, but clopidogrel activation is primarily via CYP2C19*
- While it is true that ritonavir is a notorious **CYP3A4 inhibitor**, it also significantly impacts **CYP2C19**, making this distinction clinically dangerous in the context of prodrug activation.
- Dismissing the interaction based on CYP3A4 ignores the fact that **CYP2C19** is the rate-limiting step for clopidogrel’s clinical efficacy.
*Ritonavir induces CYP2C19, leading to excessive clopidogrel activation and bleeding risk*
- Ritonavir is primarily known as a **potent inhibitor** of hepatic enzymes, not an inducer of the CYP2C19 pathway.
- An inducer would increase the conversion to the active metabolite, leading to **bleeding**, whereas ritonavir causes treatment failure due to **subtherapeutic** levels of the active drug.
*Clopidogrel induces ritonavir metabolism, decreasing antiretroviral efficacy*
- **Clopidogrel** does not possess significant **enzyme-inducing** properties and is not known to lower the therapeutic levels of protease inhibitors.
- The primary concern in this drug-drug interaction is the **failure of the antiplatelet therapy**, not the failure of the HIV regimen.
*No significant interaction exists between these medications*
- This is incorrect as the interaction is well-documented and requires the use of alternative agents like **prasugrel** or **ticagrelor** (though ticagrelor also has CYP3A4 interactions).
- Failing to recognize this lead to a high risk of **cardiovascular events** in patients with newer coronary stents.
Question 9: A 45-year-old woman with bipolar disorder controlled on lithium presents with confusion, tremor, and ataxia. Her lithium level is 2.8 mEq/L (therapeutic: 0.6-1.2). She recently started a new medication prescribed by her primary care physician for hypertension. Which antihypertensive medication most likely caused this interaction?
A. Amlodipine
B. Losartan
C. Hydrochlorothiazide (Correct Answer)
D. Metoprolol
E. Hydralazine
Explanation: ***Hydrochlorothiazide***
- Thiazide diuretics cause volume depletion, leading to increased **proximal tubule reabsorption** of both sodium and lithium, which significantly reduces **lithium clearance**.
- This interaction frequently results in **lithium toxicity**, presenting with the confusion, ataxia, and coarse tremors seen in this patient with a level of 2.8 mEq/L.
*Amlodipine*
- This is a **calcium channel blocker** that typically does not interfere with the renal handling of lithium or its serum concentrations.
- It is often considered a safer antihypertensive choice for patients on lithium therapy regarding direct **pharmacokinetic interactions**.
*Losartan*
- While **Angiotensin II Receptor Blockers (ARBs)** can sometimes increase lithium levels, the effect is generally less predictable and less profound than that of thiazides.
- They primarily affect the **distal nephron** hemodynamics rather than the aggressive proximal reabsorption triggered by thiazide-induced sodium loss.
*Metoprolol*
- Beta-blockers like metoprolol do not have a significant effect on the **renal excretion** of lithium and do not cause toxicity.
- In fact, beta-blockers are sometimes used therapeutically to treat the **fine intention tremor** associated with therapeutic lithium use.
*Hydralazine*
- Hydralazine is a **direct vasodilator** that does not impact the renal tubular transport mechanisms responsible for lithium homeostasis.
- It does not cause the **sodium depletion** required to trigger the compensatory increase in lithium retention.
Question 10: A 68-year-old man with atrial fibrillation on warfarin (INR 2.5) presents to the emergency department with severe back pain. He was started on ciprofloxacin 3 days ago for a urinary tract infection. Today his INR is 6.2 and he has no signs of bleeding. Which mechanism best explains this drug interaction?
A. Ciprofloxacin inhibits CYP2C9, decreasing warfarin metabolism
B. Ciprofloxacin displaces warfarin from plasma protein binding sites
C. Ciprofloxacin eliminates vitamin K-producing gut bacteria (Correct Answer)
D. Ciprofloxacin induces hepatic metabolism of warfarin
E. Ciprofloxacin increases renal excretion of warfarin metabolites
Explanation: ***Ciprofloxacin eliminates vitamin K-producing gut bacteria***
- Fluoroquinolones like **ciprofloxacin** disrupt the **gut microbiome**, reducing the population of bacteria responsible for **vitamin K** synthesis.
- A decrease in available vitamin K enhances the anticoagulant response of **warfarin**, leading to a significant increase in the **INR**.
*Ciprofloxacin inhibits CYP2C9, decreasing warfarin metabolism*
- While some fluoroquinolones are inhibitors, **ciprofloxacin** primarily inhibits **CYP1A2** rather than **CYP2C9**, which is the major enzyme for S-warfarin metabolism.
- Other antibiotics like **sulfamethoxazole/trimethoprim** or **metronidazole** are the classic causes of interaction via **CYP2C9 inhibition**.
*Ciprofloxacin displaces warfarin from plasma protein binding sites*
- Displacement from **albumin** can transiently increase the free fraction of a drug, but it is rarely the primary cause of a sustained, high **INR**.
- This mechanism is less clinically significant for fluoroquinolones compared to drugs like **sulfonamides** or **salicylates**.
*Ciprofloxacin induces hepatic metabolism of warfarin*
- **Induction** of hepatic enzymes would increase the metabolism of warfarin, which would **decrease the INR** and lead to subtherapeutic levels.
- Common inducers include **rifampin**, **phenytoin**, and **carbamazepine**, which have the opposite effect of what is seen in this patient.
*Ciprofloxacin increases renal excretion of warfarin metabolites*
- Increasing the **renal clearance** of drug metabolites would typically decrease the drug's activity or have no impact on the active drug concentration.
- Warfarin is heavily metabolized by the **liver** before excretion, so altered renal clearance is not a primary mechanism for **elevated INR**.
